WST West Pharmaceutical Services, Inc.
USHealthcareAs of 2026-10-09
Why WST matters now
West Pharmaceutical Services, Inc. (WST) is a US stock in Healthcare. The latest InvestLog snapshot shows $366.23 with +0.81% on the session and $25.77B in market capitalization; recent performance reads 1-month +7.93% and YTD +19.22%.
The latest financial table shown here is Q1 2026, with revenue of $844.9M, net income of $138.8M, and EPS of $1.92. Investors can compare that operating picture with valuation signals such as P/E 37.83 and FCF yield 2.0%.
InvestLog's latest related AI research is a Rating Change note titled "Barclays raises WST target to $440 from $400". The latest indexable market news headline is "West Pharma: Still A Buy, But Expectations Are Rising" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $317.50; recent insider activity includes Campbell Shane Alden filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
37.83
PEG
186.41
P/B
7.90
P/S
7.20
EV/EBITDA
27.23
DCF Value
$93.05
FCF Yield
2.0%
Div Yield
0.3%
Margins & Returns
Gross Margin
36.2%
Operating Margin
20.7%
Net Margin
16.9%
ROE
17.9%
ROA
13.2%
ROIC
15.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $844.9M | $138.8M | $1.92 |
| Q4 2025 | $805.0M | $132.1M | $1.82 |
| FY 2025 | $3.07B | $493.7M | $6.80 |
| Q3 2025 | $804.3M | $140.0M | $1.93 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$330.83
Target (Median)
$317.50
Target Range
$295.00 - $400.00
Trading Activity
Insider Trades
Related AI Research
Barclays raises WST target to $440 from $400Barclays 上调目标价 WST:$400 → $440
On 2026-10-07, Barclays raised its WST price target to $440 from $400 (+10.0%).Barclays 于 2026-10-07 将 WST 目标价上调至 $440,此前为 $400,变动幅度 +10.0%。
Morgan Stanley upgrades WST from Equal Weight to OverweightMorgan Stanley 把 WST 评级 上调:持平权重(Equal Weight) → 增持(Overweight)
On 2026-09-22, Morgan Stanley upgraded WST to Overweight from Equal Weight.Morgan Stanley 于 2026-09-22 将 WST 评级上调至 增持(Overweight),此前为 持平权重(Equal Weight)。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.18
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.